BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:GSK3862995 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of GSK3862995\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06154837-1528@assetmemo.bio
DTSTAMP:20261121T005848Z
DTSTART;VALUE=DATE:20261216
DTEND;VALUE=DATE:20261217
SUMMARY:GSK3862995: Phase 1 readout est. (NCT06154837)
DESCRIPTION:GSK3862995\, phase 1\, Chronic Obstructive Pulmonary Disease.\n
 Study: A Study for GSK3862995B in Healthy Participants and Participants Wi
 th Chronic Obstructive Pulmonary Disease\nEstimated primary completion: 16
  December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gsk38
 62995#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06154837
URL:https://assetmemo.bio/drug/gsk3862995#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07201051-1528@assetmemo.bio
DTSTAMP:20261121T005848Z
DTSTART;VALUE=DATE:20270504
DTEND;VALUE=DATE:20270505
SUMMARY:GSK3862995: Phase 2 readout est. (NCT07201051)
DESCRIPTION:GSK3862995\, phase 2.\nStudy: A Study to Assess the Effectivene
 ss and Safety of GSK3862995B in Adults With Bronchiectasis\nEstimated prim
 ary completion: 4 May 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/gsk3862995#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07201051
URL:https://assetmemo.bio/drug/gsk3862995#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
